A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 1358894 Once Daily Over 12 Week Treatment Period in Patients With Borderline Personality Disorder
Latest Information Update: 02 Feb 2024
At a glance
- Drugs BI 1358894 (Primary)
- Indications Borderline personality disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 03 Feb 2023 Status changed from active, no longer recruiting to completed.
- 20 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 19 Dec 2022 Planned primary completion date changed from 30 Nov 2022 to 19 Dec 2022.